AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
C Zhu, Y Wei, X Wei - Molecular cancer, 2019 - Springer
Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
Giving AXL the axe: targeting AXL in human malignancy
The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand
growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular …
growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular …
Evaluation of h istone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH 2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 …
S Venneti, MT Garimella, LM Sullivan… - Brain …, 2013 - Wiley Online Library
Abstract H3F3A mutations are seen in∼ 30% of pediatric glioblastoma (GBMs) and involve
either the lysine residue at position 27 (K27M) or glycine at position 34 (G34R/V). Sixteen …
either the lysine residue at position 27 (K27M) or glycine at position 34 (G34R/V). Sixteen …
[HTML][HTML] Axl as a mediator of cellular growth and survival
H Axelrod, KJ Pienta - Oncotarget, 2014 - ncbi.nlm.nih.gov
The control of cellular growth and proliferation is key to the maintenance of homeostasis.
Survival, proliferation, and arrest are regulated, in part, by Growth Arrest Specific 6 (Gas6) …
Survival, proliferation, and arrest are regulated, in part, by Growth Arrest Specific 6 (Gas6) …
Antibody-directed metal-organic framework nanoparticles for targeted drug delivery
Nanosized metal-organic frameworks (nMOFs) have shown great promise as high-capacity
carriers for a variety of applications. For biomedicine, numerous nMOFs have been …
carriers for a variety of applications. For biomedicine, numerous nMOFs have been …
Migration/invasion of malignant gliomas and implications for therapeutic treatment
CA Liu, CY Chang, KW Hsueh, HL Su… - International journal of …, 2018 - mdpi.com
Malignant tumors of the central nervous system (CNS) are among cancers with the poorest
prognosis, indicated by their association with tumors of high-level morbidity and mortality …
prognosis, indicated by their association with tumors of high-level morbidity and mortality …
Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies
M Schoumacher, M Burbridge - Current oncology reports, 2017 - Springer
A major challenge in anticancer treatment is the pre-existence or emergence of resistance to
therapy. AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor …
therapy. AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor …
Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition
The development and implementation of Immune Checkpoint Inhibitors (ICI) in clinical
oncology have significantly improved the survival of a subset of cancer patients with …
oncology have significantly improved the survival of a subset of cancer patients with …
Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma
MH Meel, MC de Gooijer, DS Metselaar… - Clinical Cancer …, 2020 - AACR
Purpose: Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain
cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 …
cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 …
Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Axl expression is deregulated in several cancer types, predicts poor overall patient survival
and is linked to resistance to drug therapy. Here, we evaluated a library of natural …
and is linked to resistance to drug therapy. Here, we evaluated a library of natural …